MedTrace Logo

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

NCT01787669 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-11-13

No results posted yet for this study

Summary

The specific aim of the study is to test the following hypothesis:

That switching between treatments from bevacizumab to Ozurdex or vice versa in eyes with diabetic macular oedema with no or incomplete response from one therapy is beneficial.

Conditions

Interventions

DRUG

Avastin (Bevacizumab)

Avastin (Bevacizumab) administered intravitreally

DRUG

Ozurdex (dexamethasone)

Ozurdex (dexamethasone) given intravitreally

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • University of Sydney

    lead OTHER

Principal Investigators

  • Samantha FRASER-BELL · SAVE SIGHT INSTITUTE, UNIVERSITY OF SYDNEY, SYDNEY EYE HOSPITAL

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-01-31
Completion
2017-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01787669 on ClinicalTrials.gov